Nuocheng Jianhua (688428): Hematoma first-mover advantage stabilizes the self-immunity pipeline and the harvest period is approaching
Nuocheng Jianhua (9969.HK): Many products whose performance is in line with expectations will soon be submitted for NDA
Nuocheng Jianhua (688428): Starting with innovation, strong execution, the pipeline in the field of hematoma and self-immunity has blossomed
Nuocheng Jianhua (688428): Positive data for TYK2 phase IIA reads out and focuses on product progress in 24 years
Nuochengjianhua-U (688428) follow-up review: TYK2 inhibitor ICP-332 released phase II clinical data, multiple research pipelines progressed smoothly
Guotai Junan: Maintaining Nuocheng Jianhua (09969)'s “Accumulation” Rating, Tyk2 Treatment with Excellent Clinical Efficacy Data for Phase II AD
Nuocheng Jianhua (9969.HK) Company Follow-up Review: TYK2 Clinical Data Excellent Chronic Disease Pipeline Will Gradually Blossom
Nuocheng Jianhua (9969.HK): The expansion of new indications for obutinib is progressing smoothly
Nuochengjianhua-B (9969.HK): Innovation leads the company to develop innovative pharmaceutical products with strong power
Nuocheng Jianhua (09969.HK): Obutinib sales are steadily increasing, and pipelines are progressing in an orderly manner in the fields of hematoma, solid tumors, and self-relief
INNOCARE PHARMA(688428):1H23 EARNINGS REVIEW:UPDATED MS DATA FOR ORELABRUTINIB AND ORDERLY ADVANCEMENT OF MULTI-FIELD R&D PIPELINES
Nuocheng Jianhua (688428) 2023 Interim Report Review: Rapid Release of Obutinib R&D Pipeline Continues to Advance
Nuocheng Jianhua-U (688428): Obutinib updates MS data and R&D pipeline in multiple fields is progressing in an orderly manner
Nuocheng Jianhua (688428) 2023 Interim Report Review: Building a Product Matrix for All Subtypes of Hematologic Tumors Multiple Products Entered Phase III Clinical Trial
Nuocheng Jianhua (9969.HK): Obutinib development is smooth and the product pipeline is gradually being enriched
INNOCARE PHARMA(9969.HK):CONSISTENT RESULTS OF ORELABRUTINIB FOR MS
Changes in Hong Kong stocks | Nuocheng Jianhua (09969) is now down more than 3%, Daimo lowered its revenue forecast and target price
Big Bank Ratings | Jefferies: Upgraded Nuocheng Jianhua's rating to buy target price to HK$15
Jefferies: Upgrading Nuocheng Jianhua-B (09969) to the “Buy” rating target price to HK$15
Nuocheng Healthcare-B (09969.HK) 2022 Annual Performance Review Report: Obutinib Doses Accelerate the 12-Week Mid-Term Analysis Data of the MS Global Phase II Clinical Trial Reached the Main Endpoint
No Data